Final efficacy data from NORSE EIGHT expected in January 2025; Resubmission of the ONS-5010 BLA targeted for Q1 CY2025; Initial commercial launches in Europe planned to commence in first half of CY2025; and Potential for US FDA approval of ONS-5010 in second half of CY2025.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK: